DTx Asia, a conference inviting healthcare companies specializing in digital therapeutics (DTx) to engage in dialogues surrounding the establishment of the industry in Asia, launched at the Novotel Ambassador Hotel in Gangnam, Seoul on Tuesday.The DTx conference also has a series in America East and
Spouses of Ambassadors in Korea had a chance to learn why Korea’s cancer mortality rate was lowest despite the lowest health cost among 21 high-income countries.The Hanaro Medical Foundation (HMF), a health checkup institution, welcomed 14 members from the Ambassadors' Spouses Association in Seoul (
Gangnam Severance Hospital (GSH) researchers demonstrated that antibody drug conjugate (ADC), REGN5093-M114, can overcome mesenchymal-epithelial transition (MET) gene-based EGFR target mutant non-small cell lung cancer (NSCLC).Lung cancer is classified into NSCLC and small cell lung cancer (SCLC) ac
HLB said on Friday that the anticancer vaccine candidate ITI-3000 aiming to treat Merkel cell cancer (MCC) via its U.S. subsidiary Immunomic Therapeutics has received fast track designation by the FDA.ITI-3000 is an anticancer vaccine made by combining lysosomal-associated membrane protein 1 (LAMP1)
Although biopharmaceutical firms commit considerable resources annually to treat neurological diseases, many still remain without a cure. This is precisely the gap that Canadian biotech, Ananda, is looking to fill by accelerating the development of therapies for neurological diseases. On a related n
Celltrion, which is developing CT-P47, the biosimilar of Actemra (tocilizumab), has set about to diversify its formulation.According to informed sources, Celltrion received approval from the Ministry of Food and Drug Safety for the domestic phase 1 clinical trial of CT-P47, which treats rheumatoid a
SK Bioscience said on Thursday that it has conducted a vaccine production training for people from developing countries at the L House, a vaccine plant located in Andong, North Gyeongsang Province, following the World Health Organization’s (WHO) designation of Korea as a global biomanufacturing trai
Orum Therapeutics, specializing in tumor-directed targeted protein degraders (TPDs), said on Tuesday that it completed the first patient dose with ORM-5029 in a U.S. phase 1 clinical trial for patients with HER2-expressing advanced solid tumors.ORM-5029 is one of two lead programs from the company’s
KAIST said on Monday that its joint research team identified the overexpression of mt-dsRNAs as a biomarker which can aid treatments of the rare and incurable autoimmune disease, Sjögren's syndrome.Sjögren's syndrome invades exocrine glands such as tear glands and salivary glands. Occular and oral d
Gangnam Severance Hospital said on Monday that it was possible to control long-term convulsions and improve cognitive development in Lennox-Gastaut syndrome (LGS) patients after sequentially applying various therapies.LGS is an intractable epilepsy with various causes of brain structural abnormaliti
The Korea Research Institute of Bioscience and Biotechnology (KRIBB) said on Thursday that they successfully developed a nano-biomaterial that can simultaneously perform precise diagnosis and photothermal therapy (PTT) of cancer cells.Cancer usually has no symptoms until it progresses considerably,
At the CEO session of the World Bio Summit (WBS 2022) in Seoul on Wednesday, both Biovac CEO Dr. Morena Makhoana and Afrigen Biologics and Vaccines Managing Director Petro Terblanche were present.In an interview with Korea Biomedical Review, they shared how they were working closely with the World H
“People talk about ‘three-minute treatments’ in medical fields. However, in reality, a one-minute treatment is not easy. Therefore, saving time in the medical field is becoming increasingly important. I expect our medical artificial intelligence (AI) solution to help make medical fields more efficie
Yonsei University Severance Hospital said on Tuesday that its researchers applied liquid biopsy circulating tumor DNA (ctDNA) tests to predict the prognosis of hepatocellular carcinoma (HCC) patients and observe post-cancer treatment reactions like immunotherapy.Liver cancer is an incurable disease
Dx&Vx said it is participating in overseas research led by Coree Group on finding new biomarkers to develop therapeutics for diabetes and obesity.To search for biomarkers, Agostino Gemelli University Policlinic, an Italy-based hospital, and Coree Group are conducting a clinical study, named, "Compar
A joint team consisting of researchers from Korea University’s College of Medicine (KUCM) and the Institute of Basic Science (IBS) confirmed that a single sequence mutation in the CYFIP2 gene could cause West syndrome, a rare brain development disease.West syndrome occurs in less than six babies per
Lotte Biologics said it decided to turn to rights issues to raise 240.5 billion won ($170.2 million) to finance the acquisition of Bristol-Myers Squibb (BMS)'s Syracuse plant in the U.S and secure operating funds.Lotte Biologics, a biopharmaceutical arm under retail giant Lotte Group, plans to issue
Chong Kun Dang Pharmaceutical said Thursday it received approval for LucenBS (ingredient: ranibizumab), a biosimilar referencing Lucentis to treat wet age-related macular degeneration (AMD), from the Ministry of Food and Drug Safety.LucenBS has secured all five indications of Lucentis -- neovascular
Samsung Biologics said it signed a contract manufacturing organization (CMO) agreement worth 420 billion won ($296 million) with GlaxoSmithKline (GSK).The contract period is from Oct. 11, 2022 to Dec. 31, 2030.However, Samsung Biologics refused to disclose which drug the deal covers, as requested by
Helixmith said on Thursday that it has acquired a Russian patent for a next-generation gene therapy candidate, pMUN+VM202, to treat neuropathic pain.The investigational neuropathic pain treatment combines insulin-like growth factor (IGF-1) and hepatocyte growth factor (HGF) genes. Accordingly, pMUN
